BOSTON— Bain Capital Real Estate and Botanic Properties have announced the acquisition of a major property in Greater Boston, setting the stage for a transformative redevelopment that will bring a new, purpose-built biomanufacturing facility to the region.
Located at 45 Crosby Drive in Bedford, Massachusetts, the property will be converted into a 154,000-square-foot Class A biomanufacturing space under their GenesisM platform—a specialized initiative focused exclusively on creating state-of-the-art facilities tailored to the evolving needs of the life sciences industry.
The transaction marks a strategic investment by GenesisM, the joint platform launched by Bain Capital and Botanic to address the acute demand for biomanufacturing infrastructure. Financial details of the acquisition were not disclosed.
The upcoming redevelopment is designed to meet the increasingly complex demands of biotech companies, offering future tenants cutting-edge specifications such as 12,000 amps of incoming electrical power, 27-foot ceiling heights, up to 18 loading berths, and 40’ x 40’ column spacing. These high-capacity features will support a range of clinical and commercial manufacturing operations, with the flexibility for multiple tenants to run highly regulated, independent facilities within the same structure.
Strategically situated on 15 acres along the Route 3 corridor, the property offers close proximity to the greater Boston workforce and one of the world’s top biotech hubs—Kendall Square—making it an ideal location for life science and manufacturing companies.
“We developed the strategy for GenesisM to support biomanufacturing tenants struggling with high capital costs, long construction timelines and lack of access to purpose-built biomanufacturing space at the right scale for their needs,” said Joe Marconi, Partner at Bain Capital. “This is an exciting and meaningful opportunity to leverage our deep experience in life science real estate to deliver purpose-built facilities designed with a true understanding of the needs of the end users, while addressing the primary pain points for tenants in today’s market – capital efficiency and speed to market. We look forward to the continued growth of GenesisM with our partner Botanic Properties as we work closely to position 45 Crosby Drive as a premier destination for biopharmaceutical companies seeking modern, efficient, and flexible manufacturing space.”
GenesisM’s “Enhanced Core” design approach is a standout feature of the platform. It aims to reduce fit-out time and construction costs for tenants while enabling scalable manufacturing space that evolves with a company’s product development lifecycle. The platform’s innovation lies in its ability to combine speed-to-market with long-term adaptability—factors crucial to biopharmaceutical companies navigating clinical and commercial production phases.
Bain Capital’s Real Estate team brings deep sector experience to the partnership, having invested in more than 7 million square feet of life science space since 2013, with a current operational portfolio exceeding 5 million square feet across major U.S. biotech hubs.
“Botanic is fortunate and proud to have found a partner in Bain Capital that truly understands the real estate needs of the life science industry,” said Joshua Zinns, Managing Principal of Botanic Properties. “Their commitment to the industry and market insights derived from across the firm’s healthcare platform give us the ability to design and deliver world class biomanufacturing assets and to take a long term, strategic approach to delivering solutions for our tenants.”
As demand for scalable, compliant, and capital-efficient manufacturing space continues to rise, the 45 Crosby Drive project aims to establish a new benchmark in biomanufacturing infrastructure—poised to meet both the urgent needs of today and the long-term ambitions of tomorrow’s leading biotech firms.
